

# **EVALUATION**

For the Provincial Stroke Rounds Planning Committee:

- To plan future programs
- For quality assurance and improvement

For **You**: Reflecting on what you've learned and how you plan to apply it can help you enact change as you return to your professional duties

For **Speakers**: The responses help understand participant learning needs, teaching outcomes and opportunities for improvement.


https://www.surveymonkey.com/r/ ZR7L9SX



Please take 2 minutes to fill out the evaluation

Thank you!

Medicine UNIVERSITY OF TORONTO





Medicine





Through this talk, participants will understand:


- 1) that stroke is not just a geriatric disease,
- 2) the varied causes and the wide range of outcomes for young adults with stroke,
- 3) the importance of early assessment and treatment, and aggressive long-term risk reduction.


R.H. Swartz

Medicine UNIVERSITY OF TORONTO






























# **ETIOLOGY OF STROKE IN YOUNG ADULTS**



#### **ETIOLOGY OF STROKE IN YOUNG ADULTS** Largest study: Helsinki young stroke registry. 1008 age 15-49. Modified **TOAST** criteria: Large artery atherosclerosis (8%) Cardioembolism (20%) Small vessel or lacunar (14%) Unknown causes (idiopathic) (33%) Other Dissection (15%) Miscellaneous (migraine, vasculitis, ٠ venous thrombosis, coagulopathies) Putaala Stroke, 2009;40:1195-1203 Medicine UNIVERSITY OF TORONTO R.H.Swartz, University of Toronto

Study	Putaala (Stroke 2009)	Cerrata (Cerebrovasc Dis 2004)	Kittner (Neurology 1998) * allowed >1 possible cause	Michael (CJNS 2000)
Age range	15-49	16-49	15-44	15-45
#	1008	273	428	356
Cardioembolic	20%	24%	31%	14%
Large vessel	8%	16%	4%	6%
Small vessel	14%	17%	20%	8%
Dissection	15%	13%	11% (** Nonathero vasculopathy)	13%
Other miscellaneous	10%	10%	31%	15%
Unidentified / Cryptogenic	33%	24%	32%	44%

#### **ETIOLOGY OF STROKE IN YOUNG ADULTS**


- Etiologies change with age even in this group
- At least 1/3 have undetermined causes
  - Fewer undetermined with increasing age
  - More large artery atherosclerosis and smallvessel disease after age 35, consistent with increasing risk factors with age


#### **ETIOLOGY: OTHER MISCELLANEOUS**


 Migraine, vasculitis, venous thrombosis, coagulopathies, hematological disorders, antiphospholipid antibody syndrome, SLE, postradiation arteriopathy, eclampsia, systemic diseases, cancer, procedures, prescriptions, infections, illicit drug use, reversible cerebral vasoconstriction syndrome, moya-moya vasculopathy, CADASIL, MELAS, Fabry's, Ehler's-Danlos Type IV, sickle cell disease, osteogenesis imperfecta, pseudoxanthoma elasticum, pregnancy-specific causes (eclampsia, HELLP, CVST, peripartum cardiomyopathy)...

R.H.Swartz, University of Toronto

Medicine UNIVERSITY OF TORONTO







#### ACUTE STROKE TREATMENT IN THE YOUNG

- Same in younger as in older rule out bleeding tPA, EVT for ischemic; BP control, reverse coagulopathies for hemorrhages (see www.strokebestpractices.ca – Hyperacute chapter).
- Young patients have at least as much benefit as older patients from both IV tPA and endovascular interventions and stroke unit care.
- Early decompressive hemicraniectomy can be considered for severe large MCA infarction to improve mortality and long-term functional outcomes. (Vahedi et al., *Lancet Neurol*, 2007)

Medicine UNIVERSITY OF TORONTO R.H. Swartz, University of Toronto

# **SECONDARY PREVENTION**

- Lifestyle change, aggressive vascular risk reduction, treat underlying conditions if found, smoking cessation, avoid recreational drug use (including marijuana –wolff et al., *Stroke* 2011; Westover et al., *Arch Gen Psychiatry* 2007)
- May get even more benefit from BP reduction.
- Ubiquitous statins controversial, but young patients were in SPARCL trial.
- Current trials of DOAC's for "ESUS" (Embolic Stroke of Uncertain Source) RESPECT including young adults.

Medicine

R.H. Swartz, University of Toronto



#### **OUTCOMES**

Large Austrian study of 2223 patients <55

• 88% good outcome. Declines with age by 3-4% per decade from 18-55 (Knoflach, *Neurology*, 2012;78:279-285)


Helsinki data suggests mortality of <3% at 1 month, but 4.7% at 1 year and 10.7% at 5 years.

Higher mortality with age, malignancy, heart failure, heavy alcohol use, diabetes, stroke severity and large artery stroke (Putaala Stroke 2009, Spengos Eur J Neurol, 2010)

GOAL (Global Outcome Assessment Life-long after stroke in young adults) multicentre retrospective individual patient data metaanalysis (Ekker et al., BMJ Open, 2019, Nov 14;9(11))

Medicine UNIVERSITY OF TORONTO


R.H.Swartz, University of Toronto





### **RECURRENCE RISKS**

- Those without risk factors have fewer recurrent strokes (4.7% vs. 13.6%), fewer other arterial events (0 vs 6%) and lower mortality (3.4% vs 14.3%). (Putaala, Stroke 2012)
- The presence of silent brain infarcts increases the risk of recurrent stroke ~2.5 times (Putaala, Neurology 2011)
- history of prior TIA also increases recurrence risk (Nedeltchev, JNNP 2005)

Medicine UNIVERSITY OF TORONTO








# LONG-TERM OUTCOMES OF THE PEOPLE WE DISCHARGE?

• Combined outcome: 9.5% in the year AFTER the highest risk period ended and 34% by 5 years

Outcomes	Stroke/TIA	Matched	Hazard Ratio	
	Patients	Controls	(95% CI)	
	N (%)	N (%)		
Composite Measure				
1 year	2496 ( <b>9.5</b> )	14212 (5.4)	2.4 (2.3-2.5)	
3 year	5036 ( <b>23.6</b> )	29229 (13.6)	2.2 (2.1-2.3)	
5 year	5328 ( <mark>34.0</mark> )	32797 (21.1)	· · · · · ·	
			2.1 (2.1-2.2)	
	J. Edwar	ds et al., CMAJ, 2017		
Medicine				



Long-term Outcomes of <b>Young Stroke</b>							
	ed) and at	2% @ 1 year <b>(AFTE</b> ; 1.2% per year for	0				
Compared to m and remains >8		ntrols, the 1-year r rs.	risk is >7 fold				
Risk remains e risk factors.	levated ev	en after accountin	g for vascular				
Outcomes	Stroke/TIA Patients N (%)	Adjusted Hazard Ratio for young vs young controls (95% CI)	Adjusted Hazard Ratio for older vs. older controls (95% CI)				
Composite Measure							
1 year	29 (2.2)	7.3 (4.0-13.6)	<b>1.3</b> (1.2-1.3)				
3 year	51 (4.7)	<b>4.3</b> (2.6-7.3)	1.4 (1.3-1.4)				
5 year	56 (7.1)	5.2 (2.8-9.4)	<b>1.3</b> (1.3-1.4)				
Medicine UNIVERSITY OF TOR	onto	J. Edwards et al., JA https://doi.org/10.1161/JA					




# Is "GOOD" GOOD ENOUGH?


> 2.4 years post-stroke, 68% had "excellent outcome" (mRS 0-1). BUT:

- **54%** cognitive impairment (MoCA <26)
- 52% some restrictions in reintegration to society (RNLI > 0).
- **30%** were both, cognitively impaired and had restrictions
- **32%** endorsed symptoms of depression (PHQ-2 >0)
- 19% reported a change in work status

A. Kapoor et al., Stroke, 2017

Medicine








# **COMPLICATIONS POST-STROKE**


Many common comorbidities (examples):


- **D**epression, Anxiety
- Obstructive Sleep Apnea
- Cognitive impairment
- Communication limitations
- Gait, mobility and falls
- Continence challenges
- Seizure risk

Medicine UNIVERSITY OF TORONTO


R.H.Swartz, University of Toronto











# **SUMMARY**

- An organized approach to etiologies, investigations, treatment and prevention is needed for stroke in young adults and in pregnancy.
- A holistic approach to the person and impact of the event are key to helping patients and families live well after stroke.
- Ongoing, aggressive vascular risk reduction approaches are important to minimize long-term recurrence risks.

Medicine





